journal article·2017-11-28Open access

Macrophage repolarization using CD44-targeting hyaluronic acid–polylactide nanoparticles containing curcumin

Raana Farajzadeh, Nosratollah Zarghami, Hamed Serati-Nouri, Zahra Momeni-Javid, Taher Farajzadeh, Sepideh Jalilzadeh-Tabrizi, Shima Sadeghi-Soureh, Neda Naseri, Younes Pilehvar-Soltanahmadi

Abstract

The aim of this study was to evaluate the efficiency of using a natural substance, curcumin, encapsulated in CD44-targeting hyaluronate–polylactide (HA-PLA) nanoparticles (NPs) for the modulation of macrophage polarity from the pro-inflammatory M1 to anti-inflammatory M2 phenotype. For this purpose, the characterization of the NPs was monitored using 1HNMR, FTIR, DLS and FE-SEM. The effects of curcumin-encapsulated HA-PLA NPs on the viability of LPS/IFN-γ stimulated peritoneal macrophages were determined using MTT assay. The cellular uptake of free curcumin and nano-formulated curcumin was assessed using confocal microscopy. Also, the expression levels of iNOS-2 (M1 marker), Arg-1 (M2 marker) and also pro-inflammatory cytokines were measured by real-time PCR. Data showed that the nano-formulated curcumin with spherical shape, an average diameter of 102.5 nm and high cellular uptake was significantly less toxic to peritoneal macrophages. Furthermore, the nano-formulated curcumin effectively indicated a reduction in iNOS-2 and an increase in Arg-1 levels than free curcumin. The change in macrophage phenotype by curcumin-encapsulated HA-PLA NPs could suppress the inflammation in LPS/IFN-γ stimulated macrophages as evidenced by a major reduction in pro-inflammatory cytokines. Conclusively, the results suggested that the curcumin formulation with CD44-targeting HA-PLA NPs might be a promising platform for the treatment of inflammatory diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Immune cells in cancer · Galectins and Cancer Biology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;

Stem Cell Research Center, Tabriz University of Medical Science, Tabriz, Iran;

Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Microbiology, Zanjan Basic Sciences and Medicine Branch, Islamic Azad University, Zanjan, Iran;

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran;

Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia

References (40)

Show source-provided references
1. 10.1080/21691401.2017.133702210.1080/21691401.2017.1337022 ↗
2. 10.12703/P6-1310.12703/P6-13 ↗
3. Wang N · Front Immunol · 2015 · 5 · 230
4. 10.1371/journal.pone.015202410.1371/journal.pone.0152024 ↗
5. 10.1080/21691401.2017.136768910.1080/21691401.2017.1367689 ↗
6. 10.7150/ijbs.887910.7150/ijbs.8879 ↗
7. 10.1159/00043012610.1159/000430126 ↗
8. 10.1097/FJC.000000000000007910.1097/FJC.0000000000000079 ↗
9. Gao S · Circulation · 2014 · 130 · A17425
10. 10.1016/j.ijpharm.2016.05.03910.1016/j.ijpharm.2016.05.039 ↗
11. 10.2174/092986732366616042511370510.2174/0929867323666160425113705 ↗
12. 10.2174/138955751766617030811214710.2174/1389557517666170308112147 ↗
13. 10.2174/187152061666616081512453710.2174/1871520616666160815124537 ↗
14. 10.2174/187152061766617021311575610.2174/1871520617666170213115756 ↗
15. 10.1055/s-0043-11963510.1055/s-0043-119635 ↗
16. Rami A · Adv Pharma Bull · 2013 · 3 · 127
17. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
18. 10.7314/APJCP.2014.15.20.893110.7314/APJCP.2014.15.20.8931 ↗
19. 10.3109/21691401.2014.98280310.3109/21691401.2014.982803 ↗
20. 10.1080/21691401.2017.134787910.1080/21691401.2017.1347879 ↗
21. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
22. 10.17795/ijcp-419010.17795/ijcp-4190 ↗
23. 10.1080/21691401.2016.121685410.1080/21691401.2016.1216854 ↗
24. 10.1080/21691401.2016.127692210.1080/21691401.2016.1276922 ↗
25. 10.7314/APJCP.2015.16.18.825910.7314/APJCP.2015.16.18.8259 ↗
26. 10.1038/srep1663210.1038/srep16632 ↗
27. Sharma M · Artif Cells Nanomed Biotechnol · 2017 · 1
28. 10.1016/j.actbio.2009.05.01910.1016/j.actbio.2009.05.019 ↗
29. 10.1080/21691401.2017.135873110.1080/21691401.2017.1358731 ↗
30. Anganeh MT · Int J Biosci · 2014 · 4 · 134
31. 10.3109/21691401.2015.112962810.3109/21691401.2015.1129628 ↗
32. 10.1080/21691401.2017.133702010.1080/21691401.2017.1337020 ↗
33. 10.3109/21691401.2016.114673610.3109/21691401.2016.1146736 ↗
34. 10.3390/polym602034610.3390/polym6020346 ↗
35. 10.1016/j.actbio.2013.03.00510.1016/j.actbio.2013.03.005 ↗
36. 10.1016/j.progpolymsci.2013.05.01410.1016/j.progpolymsci.2013.05.014 ↗
37. 10.3390/ijerph1401001110.3390/ijerph14010011 ↗
38. 10.1016/S0142-9612(99)00129-510.1016/S0142-9612(99)00129-5 ↗
39. 10.1016/j.yjmcc.2015.04.02510.1016/j.yjmcc.2015.04.025 ↗
40. 10.5051/jpis.2011.41.3.15710.5051/jpis.2011.41.3.157 ↗